MMVsupported projects Research Lead optimization Pyrazines GSK Phenotypic

MMV-supported projects Research Lead optimization Pyrazines GSK Phenotypic Lead Mitsubishi Tanabe Intra-muscular Calibr Phenotypic Lead BMS GWT 1 Eisai Molecular Target DDU Dundee Miniportfolio Novartis 4 -aminoquinoline Molecular Target UCB DHODH Broad DHODH UTSW/ UW/ Monash Translational Candidate profiling MMV 1581373 Novartis MMV 1793609 Kentucky Human volunteers Preclinical MMV 371 Janssen MMV 183 (Trop. IQ) MMV 646 (Jacobus) INE 963 Novartis M 5717 Merck KGa. A ZY 19489 Zydus Cadila Atoguanil Ipca Product development Patient exploratory Ganaplacide / Lumefantrine Novartis Cipargamin Novartis Ferroquine (Sanofi) MMV 533 (Sanofi) Patient confirmatory Regulatory review Dihydroartemisininpiperaquine dispersible 4 Alfasigma Tafenoquine paediatric Artemether lumefantrine <5 kg Sulfadoxinepyrimethamine Novartis Access GSK 11 Universal Corporation Sulfadoxinepyrimethamine Swipha/Biogaran Sulfadoxinepyrimethamine Emzor Pharmaceutical GSK 701 GSK Approved/ERP Artemetherlumefantrine Dispersible Novartis Artesunate for Injection Fosun Pharma Merck KGa. A-UCT Ipca Alfasigma 4 Sanofi MMV support to projects may include financial, in-kind, and advisory activities. Footnotes: Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ. │ Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing. │ WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers. │ paediatric formulation. │ via a bioequivalence study. Past partners are in brackets (-). Brand names 1: Coartem® Dispersible; 2: Artesun®; 3: Larinate® 60 mg; 4: Eurartesim®; 5: Pyramax® tablets or granules; 6: ASAQ Winthrop®; 7: SPAQ-COTM; 8: Supyra® 9: 100 mg Artesunate Rectocaps; 10: Artecap. TM; 11: Kozenis or Krintafel (Trademarks owned or licensed by GSK) Artesunatemefloquine Cipla Sulfadoxinepyrimethamine+ amodiaquine dispersible 5 5 6 7 8 Artesunate rectal capsules Cipla 9 Artesunate rectal capsules Strides Pharma Artesunateamodiaquine UNICAMP February 2021 3 Pyronaridineartesunate Shin Poong Fosun Pharma S Kant Dihydroartemisininpiperaquine Shin Poong Azabenzimidazole 2 Artesunate for Injection Pyronaridineartesunate granules Phenotypic Lead 1 Sulfadoxinepyrimethamine+ amodiaquine dispersible 10 Tafenoquine GSK 11

Footnotes: MMV-supported projects Target Product Profiles and Target Candidate Profiles MMV has defined Target Product Profiles and Target Candidate Profiles for medicines to support the eradication campaign. Macintyre F et al. , “Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria. ” Malar J. 2018 Nov 1; 17(1). Burrows JN et al. , “New developments in anti‑malarial target candidate and product profiles. ” Malar J (2017) 16: 26 (updates the previous profiles in Burrows J et al. , Malar J 2013 12: 187). Target Product Profiles indicated by bars at the bottom of each compound box Target Candidate Profiles activities for each individual molecule, indicated by symbols added to compounds in the translational or product development portfolio Asexual blood stages Burrows et al. , 2013 (TCP-1, 2) Burrows et al. , 2017 TCP-1 Relapse prevention (TCP-3 a) TCP-3 Intermittent preventive treatment (TPP-1) Transmission reduction (TCP-3 b) TCP-5, 6 Products targeting prevention of relapse for P. vivax (TPP-1) Causal prophylaxis (TCP- 4) TCP-4 3 -day cure, artemisinin-based combination therapies (TPP-1) Uncomplicated malaria treatments for single-exposure radical cure (SERC) and/or resistance management (TPP-1) Severe malaria treatment / pre-referral intervention (TPP-1) Prophylaxis (TPP-2) February 2021